Michel Vounatsos | Chief Executive Officer |
Joe Mara | Vice President and Head of Investor Relations |
Michael Ehlers | Executive Vice President, Research & Development |
Jeffrey Capello | Chief Financial Officer and Executive Vice President |
Al Sandrock | Chief Medical Officer |
Cory Kasimov | JPMorgan |
Terence Flynn | Goldman Sachs |
Umer Raffat | Evercore |
Geoffrey Porges | SVB Leerink |
Michael Yee | Jefferies |
Ronny Gal | Bernstein |
Phil Nadeau | Cowen and Company |
Matthew Harrison | Morgan Stanley |
Salim Syed | Mizuho |
Brian Abrahams | RBC Capital Markets |
Paul Matteis | Stifel |
Evan Seigerman | Crédit Suisse |
Carter Gould | UBS |
Mohit Bansal | Citigroup |
Good morning. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2019 Financial Results and Business Update. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session.